Maackiain

Synonyms: DL-​Maackiain
Maackiain(DL-Maackiain)是一种口服有效的多靶点抑制剂,具有抗肿瘤活性和神经保护作用,能够激活 AMPK、NLRP3 和 Nrf2/HO-1 通路并抑制 NF-κB、mTOR、MAO-B、NFATc1 及 PKCδ 等关键靶点,从而精细调控细胞凋亡(apoptosis)、自噬(autophagy)和焦亡(pyroptosis)等过程,同时有效抑制小胶质细胞活化、破骨细胞形成及肿瘤细胞的增殖与侵袭,并保护多巴胺能神经元免受损伤,可用于阿尔茨海默病、骨质疏松症、脓毒症及登革热等多种疾病的研究。
产品编号: MS-I01499 纯度: 99.83% CAS No.: 19908-48-6 分子式: C16H12O5 分子量: 284.27
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Maackiain(DL-Maackiain)是一种口服有效的多靶点抑制剂,具有抗肿瘤活性和神经保护作用,能够激活 AMPK、NLRP3 和 Nrf2/HO-1 通路并抑制 NF-κB、mTOR、MAO-B、NFATc1 及 PKCδ 等关键靶点,从而精细调控细胞凋亡(apoptosis)、自噬(autophagy)和焦亡(pyroptosis)等过程,同时有效抑制小胶质细胞活化、破骨细胞形成及肿瘤细胞的增殖与侵袭,并保护多巴胺能神经元免受损伤,可用于阿尔茨海默病、骨质疏松症、脓毒症及登革热等多种疾病的研究。

生物实验数据

生物活性 Maackiain (DL-Maackiain) is an orally effective multi-target inhibitor with antitumor activity and neuroprotective effects that activates the AMPK, NLRP3, and Nrf2/HO-1 pathways while inhibiting key targets such as NF-κB, mTOR, MAO-B, NFATc1, and PKCδ, thereby finely regulating processes including apoptosis, autophagy, and pyroptosis; it also effectively inhibits microglial activation, osteoclast formation, and tumor cell proliferation and invasion, protects dopaminergic neurons from damage, and can be used for research on various diseases such as Alzheimer's disease, osteoporosis, sepsis, and dengue fever.
IC50 & Target Xp Parasitol (aedes aegypti mosquito):21.95 µg/mL (LD50)
体外研究
(In Vitro)

Maackiain 对大肠杆菌 (Escherichia coli)、阴沟肠杆菌 (Enterobact cloacae) 或金黄色葡萄球菌 (Staphylococcus aureus) 均无直接杀菌或抑菌活性。
Maackiain (10-100 ng/mL; 预孵育 30 min; 与 LPS 共孵育 24 h) 以剂量依赖的方式抑制 LPS 诱导的 RAW264.7 细胞促炎细胞因子 IL-1β、IL-6 和 TNF-α 的产生、抑制 RAW264.7 细胞中 LPS 诱导的 NF-κB p65 核转位;并抑制氧化应激,减少 ROS 生成、恢复线粒体膜电位,以及恢复 GSH、MDA 和 TEAC 水平。
Maackiain (100 ng/mL;预孵育 3 h,于 AMPK/Nrf2 抑制剂预处理后进行,随后与 LPS 共孵育 24 h) 在 RAW264.7 细胞中通过激活 AMPK/Nrf2/HO-1 通路发挥抗氧化和抗炎活性。
Maackiain (10-50 μM;6 h) 可呈剂量依赖性抑制 Aβ42 (10 μM; 24 h) 诱导的 PC12 细胞凋亡、氧化应激、炎症反应、细胞损伤和活力丧失;并促进 PC12 细胞中 Nrf2 的核转位,且不改变总 Nrf2 的表达。
Maackiain (5-40 μM;5 天) 可呈剂量依赖性地抑制 RANKL 诱导的小鼠骨髓巨噬细胞破骨细胞形成;并在 40 μM 剂量下,破坏成熟小鼠破骨细胞中功能性 F-actin 带的形成。
Maackiain (20-40 μM;5 天) 可下调受 RANKL 刺激的小鼠骨髓巨噬细胞中破骨细胞分化及功能相关关键基因的表达。
Maackiain (40 μM;1-5 天) 抑制 RANKL 刺激的小鼠骨髓巨噬细胞中破骨细胞特异性蛋白 c-Fos、Integrin β3、MMP9、CTSK 和 NFATc1 的表达;同时,下调NFATc1 蛋白水平并抑制其核转位。
Maackiain (40 μM;1 h) 可阻断 IκB-α 降解和 p65 磷酸化,抑制 RANKL 诱导的小鼠骨髓巨噬细胞中 NF-κB 通路的激活,从而减弱 RANKL 诱导的小鼠骨髓巨噬细胞内钙振荡。
Maackiain (50-100 ng/mL;LPS 预处理 3 h、5 μM 尼日利亚菌素 (MS-O56514) 孵育 1 h 后序贯处理 1 h) 可在经 LPS 预处理的人单核细胞系 dTHP-1 中增强 5 μM 尼日利亚菌素诱导的 caspase-1 活化及成熟 IL-1β 的产生,且在 50 ng/mL 和 100 ng/mL 浓度下呈现剂量依赖性效应。
Maackiain (2.5-40 μM;LPS 孵育后 24 h) 可强效抑制 LPS 刺激的 BV2 小胶质细胞中 NO 的生成,在 20 μM 时作用最强,且在 20 μM 以下浓度呈现浓度依赖性响应。
Maackiain (10-40 μM;LPS 孵育后 24 h) 可强效抑制 BV2 小胶质细胞中 LPS 诱导的脂质过氧化,且 40 μM 剂量的抗氧化活性强于 Ferrostatin-1。
Maackiain (100 ng/mL;24 h) 可浓度依赖性地抑制人宫颈癌 HeLa 和 SiHa 细胞的增殖,并诱导人宫颈癌 HeLa 和 SiHa 细胞发生自噬 (LC3-II 与 Beclin-1 表达水平升高、自噬体形成),和诱导细胞凋亡。
Maackiain (75 μM;3 天) 诱导人早幼粒白血病 HL-60 细胞发生 DNA 片段化、凋亡小体形成,且该作用可被抗氧化剂 N-acetyl-L-cysteine (5 mM;预孵育 2 h) 预处理所抑制。
(-)-maackiain (50-150 μM;24 h) 可抑制 IgE/抗原诱导的 RBL-2H3 细胞中 IL-4 mRNA 的上调,而人工合成的 (+)-maackiain 则无显著抑制活性。
(-)-Maackiain (20、40 μM;24 h) 抑制 HeLa 细胞中 PMA 诱导的 PKCδ 上 Tyr311 的磷酸化。
(-)-Maackiain (30 μM;24 h) 可抑制佛波酯 (PMA) 诱导的蛋白激酶 Cδ(PKCδ) 向 HeLa 细胞高尔基体的转位。

Cell Viability Assay

Cell Line: RAW264.7 mouse macrophage cells
Concentration: 10-300 ng/ml
Incubation Time: 24 h
Result: Showed no obvious effect on cell viability at 10, 50, or 100 ng/ml. Slightly decreased cell viability at 300 ng/ml.

Western Blot Analysis

Cell Line: RAW264.7 mouse macrophage cells
Concentration: 100 ng/ml (time-dependent assay); 10-100 ng/ml (dose-dependent assay)
Incubation Time: 3-24 h (time-dependent assay; 100 ng/ml); 24 h (dose-dependent assay; 10-100 ng/ml)
Result: Increased nuclear Nrf2 levels (elevated at 3 h, peaked at 12 h), decreased cytoplasmic Nrf2 levels, increased HO-1 levels, and increased p-AMPKα levels in a time-dependent manner at 100 ng/ml. Increased nuclear Nrf2 levels, decreased cytoplasmic Nrf2 levels, increased HO-1 levels, and increased p-AMPKα levels in a dose-dependent manner at 10, 50, 100 ng/ml for 24 h.

Cell Viability Assay

Cell Line: rat pheochromocytoma PC12 cells
Concentration: 10-50 μM
Incubation Time: 6 h (pretreatment); 24 h (Aβ42 exposure)
Result: Increased cell viability relative to Aβ42-only treated cells. Decreased LDH activity relative to Aβ42-only treated cells. Showed statistically significant dose-dependent protective effects at all tested concentrations.

Apoptosis Analysis

Cell Line: rat pheochromocytoma PC12 cells
Concentration: 10-50 μM
Incubation Time: 6 h (pretreatment); 24 h (Aβ42 exposure)
Result: Decreased TUNEL-positive cell counts relative to Aβ42-only treated cells. Reduced caspase-3 activity relative to Aβ42-only treated cells. Showed statistically significant dose-dependent anti-apoptotic effects at all tested concentrations.

Western Blot Analysis

Cell Line: LPS-primed differentiated THP-1 (dTHP-1) human monocyte cells
Concentration: 50-100 ng/mL
Incubation Time: 1 h (sequential treatment after 3 h LPS priming and 1 h 5 μM nigericin incubation)
Result: Amplified nigericin-induced cleavage of pro-caspase-1 to its active p20 subunit and pro-IL-1β to mature IL-1β, with a dose-dependent effect at 50 and 100 ng/mL. Did not alter LPS-induced pro-IL-1β production when used alone with LPS. Significantly increased mature IL-1β release when combined with nigericin.

Western Blot Analysis

Cell Line: MPL-primed dTHP-1 human monocyte cells
Concentration: 100 ng/mL
Incubation Time: 1 h (sequential treatment after 3 h MPL priming and 1 h nigericin incubation at 1 or 2 μM)
Result: Amplified nigericin-induced cleavage of pro-caspase-1 to p20 and mature IL-1β production in MPL-primed cells, even at reduced nigericin concentrations (1 or 2 μM). Did not increase IL-1β release relative to MPL priming alone when used alone.

Apoptosis Analysis

Cell Line: human cervical cancer HeLa cells, human cervical cancer SiHa cells
Concentration: 0-100 μM (alone); 50 μM (combined with cisplatin)
Incubation Time: 24 h
Result: Induced apoptosis in HeLa and SiHa cells in a concentration-dependent manner at 50, 100 μM, increasing the percentage of apoptotic cells and upregulating expression of cleaved PARP1, cleaved Caspase 3, cleaved Caspase 7, and cleaved Caspase 9. Enhanced cisplatin-induced apoptosis and apoptotic protein expression when used in combination at 50 μM.

Western Blot Analysis

Cell Line: human cervical cancer HeLa cells, human cervical cancer SiHa cells
Concentration: 0-100 μM
Incubation Time: 24 h
Result: Increased phosphorylated AMPK (p-AMPK) levels in a concentration-dependent manner. Decreased phosphorylated mTOR (p-mTOR), phosphorylated p70 S6K (p-p70 S6K), and phosphorylated 4E-BP1 (p-4E-BP1) levels in a concentration-dependent manner. Had no effect on total AMPK, mTOR, p70 S6K, 4E-BP1, ACC, or phosphorylated ACC (p-ACC) levels.

Real Time qPCR

Cell Line: HeLa cells
Concentration: 10-30 μM (purified (-)-maackiain); 10, 30 μM (synthesized (-)-maackiain, synthesized (+)-maackiain)
Incubation Time: 24 h (pre-incubation)
Result: Significantly suppressed PMA-induced H1R mRNA elevation at all tested concentrations (purified (-)-maackiain). Significantly suppressed PMA-induced H1R mRNA elevation at 30 μM (synthesized (-)-maackiain). Significantly suppressed PMA-induced H1R mRNA elevation at 10 and 30 μM (synthesized (+)-maackiain).
体内研究
(In Vivo)

Maackiain (2.5-5 mg/kg;腹腔注射;CLP 术前 12 小时单次给药) 可通过剂量依赖性降低死亡率、器官损伤、全身炎症反应及氧化应激,在小鼠中发挥对 CLP 诱导脓毒症的保护作用;其中 5 mg/kg 剂量可将 7 天死亡率降至 40%。
Maackiain (25-50 mg/kg;灌胃;每日给药;连续 14 天) 可改善雄性 C57BL/6 小鼠中 LPS 诱导的认知障碍,增加正常神经元数量,抑制小胶质细胞活化,并降低大脑皮层促炎介质水平,其中 50 mg/kg 剂量在多数指标中表现出更优的药效。
Maackiain (5 mg/kg; 腹腔注射; 每 2 天 1 次;共注射 6 次) 可将裸鼠的宫颈肿瘤重量降至对照组的约 40%,并较对照组抑制 50% 的肿瘤生长,且不会引发明显的全身毒性。
Racemic maackiain (5-20 mg/kg;灌胃;每日;连续 21 天) 可缓解 TDI 诱导的 Brown Norway 大鼠变应性鼻炎症状,并抑制 TDI 诱导的 H1R 与 IL-4 基因表达上调,其中每日灌胃 5、10、20 mg/kg 并连续给药 21 天的剂量均显现出显著效果。
Maackiain (10-50 μg/mL;浸浴处理;单次暴露) 对埃及伊蚊 4 龄幼虫表现出强效杀幼虫活性,在 48 h 时的 LC50 为 21.95 μg/mL。

Animal Model: C57/BL6 (6-week-old male)
Dosage: 2.5 mg/kg; 5 mg/kg
Administration: i.p.; single dose 12 hours pre-CLP
Result: Reduced 7-day mortality rate from ~90% to 60% (2.5 mg/kg) and to 40% (5 mg/kg).\nImproved clinical scores of CLP-induced septic mice in a dose-dependent manner.\n
Significantly alleviated CLP-induced pathological lesions in the lung, liver, spleen, and kidney.\nReduced serum levels of inflammatory cytokines IL-1β, IL-6, and TNF-α in a dose-dependent manner at 12 and 24 hours post-CLP.\n
Reversed CLP-induced reductions in serum GSH levels and Trolox Equivalent Antioxidant Capacity (TEAC), and reversed CLP-induced increases in serum malondialdehyde (MDA) levels in a dose-dependent manner.\n
Abrogated Maackiain-induced reductions in serum IL-1β, IL-6, and TNF-α levels at 12 and 24 hours post-CLP when pre-treated with Compound C or ML385.\n
Reversed Maackiain-induced improvements in serum GSH levels, TEAC, and MDA levels when pre-treated with Compound C or ML385.\n
Reduced the survival rate of Maackiain-treated septic mice, worsened their clinical scores, and diminished Maackiain's protective effects against CLP-induced organ injury when pre-treated with Compound C or ML385.
Animal Model: C57BL/6 (male, 7-8 weeks old, 18-22 grams, SPF-grade)
Dosage: 25 mg/kg; 50 mg/kg
Administration: i.g.; daily; 14 days
Result: Significantly reduced escape latency in the Morris Water Maze training phase compared to the LPS group.
Increased the time mice spent in the target quadrant during the probe trial and increased platform crossings at 50 mg/kg dose; showed no significant difference in these probe trial metrics vs the LPS group at 25 mg/kg dose.\n
Increased the number of normal neurons in the hippocampus at 50 mg/kg dose, and increased the number of normal neurons in the cortex at 25 mg/kg dose, both compared to the LPS group.\n
Reduced IBA-1 fluorescence intensity (a marker of microglial activation) in brain tissue compared to the LPS group at both doses, with the 50 mg/kg dose showing a greater inhibitory effect than the 25 mg/kg dose.\n
Reduced COX-2 expression in the cortex compared to the LPS group at both doses, with the 50 mg/kg dose showing the strongest inhibitory effect.\n
Reduced IL-6 expression in the cortex compared to the LPS group at both doses, with the 50 mg/kg dose showing a greater inhibitory effect; no significant differences in hippocampal IL-6 levels were observed between either maackiain dose group and the LPS group.
Animal Model: nude mice (4-week-old, unspecified gender)
Dosage: 5 mg/kg
Administration: i.p.; once every 2 days; 6 total injections
Result: Reduced mean tumor volume to ~700 mm3 (control ~1400 mm3) 21 days after first treatment.\n
Reduced mean tumor weight to ~40% of control levels.\n
Caused no significant changes in mouse body weight.\n
Showed no toxicity to the heart, kidney, or liver via hematoxylin and eosin staining.
Animal Model: Brown Norway rats (6-week-old male, 200-250 g, allergic rhinitis model via TDI sensitization and challenge)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: p.o.; daily; 21 days
Result: Significantly reduced the number of sneezes and suppressed TDI-induced upregulation of IL-4 mRNA in nasal mucosa (5 mg/kg).\n
Significantly reduced the number of sneezes, suppressed TDI-induced upregulation of IL-4 mRNA in nasal mucosa, and showed a trend toward reducing nasal scores (10 mg/kg).\n
Significantly reduced the number of sneezes, reduced nasal scores, and suppressed TDI-induced upregulation of both H1R and IL-4 mRNA in nasal mucosa (20 mg/kg).
Animal Model: Rockefeller (4th instar larvae)
Dosage: 10, 20, 30, 35, 40, 50 μg/mL
Administration: immersion; single exposure
Result: Exhibited larvicidal activity with a 48-hour LC50 value of 21.95 μg/mL, with a 95% confidence interval of 19.27-24.46 μg/mL.
性状 固体
颜色 White to off-white

化学信息

分子量 284.27
分子式 C16H12O5
CAS No. 19908-48-6
别名 DL-​Maackiain

储存&溶解度

体内实验配方
10% DMSO+90% Saline: < 10 mg/mL (35.18 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (35.18 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 250 mg/mL (879.45 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.5178 mL17.5889 mL35.1778 mL87.9446 mL
5 mM0.7036 mL3.5178 mL7.0356 mL17.5889 mL
10 mM0.3518 mL1.7589 mL3.5178 mL8.7945 mL
15 mM0.2345 mL1.1726 mL2.3452 mL5.8630 mL
20 mM0.1759 mL0.8794 mL1.7589 mL4.3972 mL
25 mM0.1407 mL0.7036 mL1.4071 mL3.5178 mL
30 mM0.1173 mL0.5863 mL1.1726 mL2.9315 mL
40 mM0.0879 mL0.4397 mL0.8794 mL2.1986 mL
50 mM0.0704 mL0.3518 mL0.7036 mL1.7589 mL
60 mM0.0586 mL0.2931 mL0.5863 mL1.4657 mL
80 mM0.0440 mL0.2199 mL0.4397 mL1.0993 mL
100 mM0.0352 mL0.1759 mL0.3518 mL0.8794 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础